Atossa Therapeutics, Inc.
ATOS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001488039
No open-market purchases or sales by Atossa Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $2.60M in total; no superinvestor holds it.
Holders of 5% or more of ATOS
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Atossa Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Atossa Therapeutics, Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
3 Schedule 13D and 13G filings on Atossa Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jul 29, 202511:26 AM ET | Vanguard Group Inc | 13G/A | 4.51%5.83M shares | –Below 5% | Jun 30, 2025 | SEC |
| Jul 16, 20257:02 PM ET | BlackRock, Inc. | 13G/A | 1.60%2.09M shares | –Below 5% | Jun 30, 2025 | SEC |
| Feb 7, 20254:09 PM ET | CVI Investments, Inc.and 1 other | 13G/A | 4.30%5.66M shares | –Below 5% | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Atossa Therapeutics, Inc. shares.
No Form 144 notices for Atossa Therapeutics, Inc. are on file.